• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Teva Pharmaceutical Industries

Teva Pharmaceutical Industries

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  5. Research
  1. United States Tardive Dyskinesia Market: Size, Trends & Forecasts 2016-2025 Featuring Valeant Pharmaceuticals, Neurocrine Biosciences and Teva Pharmaceutical Industries - Research and Markets

    United States Tardive Dyskinesia Market: Size, Trends & Forecasts 2016-2025 Featuring Valeant Pharmaceuticals, Neurocrine Biosciences and Teva Pharmaceutical Industries - Research and Markets

  2. Teva Receives Positive Outcome for COPAXONE® Label in Europe

    Teva Receives Positive Outcome for COPAXONE® Label in Europe

  3. Teva Secures European Approval of Trisenox® for First Line Treatment of Low to Intermediate Risk Acute Promyelocytic Leukemia (APL)

    Teva Secures European Approval of Trisenox® for First Line Treatment of Low to Intermediate Risk Acute Promyelocytic Leukemia (APL)

  4. 2017 OurCrowd Global Investor Summit to Take Place in Jerusalem, Israel on Feb. 16, 2017

    2017 OurCrowd Global Investor Summit to Take Place in Jerusalem, Israel on Feb. 16, 2017

  5. Valeant Deal Talks Collapse Over Price -- WSJ

    Valeant Deal Talks Collapse Over Price -- WSJ

  6. News Highlights: Top Equities Stories of the Day

    News Highlights: Top Equities Stories of the Day

  7. CORRECTING and REPLACING Verily Life Sciences Launches Liftware™ Level Device to Help People with Limited Hand and Arm Mobility Eat with Confidence

    CORRECTING and REPLACING Verily Life Sciences Launches Liftware™ Level Device to Help People with Limited Hand and Arm Mobility Eat with Confidence

  8. Teva Revenue Rises on Allergan Deal, But Its Specialty Drugs Saw Pressure

    Teva Revenue Rises on Allergan Deal, But Its Specialty Drugs Saw Pressure

  9. The Corporate Reputation of Pharma 2015 - The Perspective of 110 Patient Groups with an Interest in Skin Conditions - Research and Markets

    The Corporate Reputation of Pharma 2015 - The Perspective of 110 Patient Groups with an Interest in Skin Conditions - Research and Markets

  10. The Corporate Reputation of Pharma 2015-2016 - The Perspective of 139 Patient Groups with an Interest in Diabetes - Research and Markets

    The Corporate Reputation of Pharma 2015-2016 - The Perspective of 139 Patient Groups with an Interest in Diabetes - Research and Markets

12345
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.